Literature DB >> 12556914

Mutational analysis of the nicotinic acetylcholine receptor alpha 4 subunit gene in attention deficit/hyperactivity disorder: evidence for association of an intronic polymorphism with attention problems.

R D Todd1, E A Lobos, L-W Sun, R J Neuman.   

Abstract

Recent studies suggest the presence of genetically distinct subtypes of attention deficit/hyperactivity disorder (ADHD) and that attention problems can be treated with receptor subtype selective nicotine agonists. In this study, individuals with two independent familial subtypes of ADHD defined by latent class analysis were systematically screened for sequence variations in the coding regions and intron/exon junctions of the nicotinic acetylcholine receptor alpha 4 subunit gene (CHRNA4). Common polymorphisms were used for transmission disequilibrium test (TDT) analyses. A significant association was found for a 5' intron 2 single nucleotide polymorphism and severe inattention problems (P = 0.007, effect size = 4, 95% CI 1.3-14.1). The location of the polymorphism is compatible with it affecting pre-mRNA stability or splicing.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12556914     DOI: 10.1038/sj.mp.4001257

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  41 in total

1.  Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.

Authors:  Allison B Gold; Caryn Lerman
Journal:  Hum Genet       Date:  2012-01-31       Impact factor: 4.132

2.  Variation in the nicotinic acetylcholine receptor gene cluster CHRNA5-CHRNA3-CHRNB4 and its interaction with recent tobacco use influence cognitive flexibility.

Authors:  Huiping Zhang; Henry R Kranzler; James Poling; Joel Gelernter
Journal:  Neuropsychopharmacology       Date:  2010-07-14       Impact factor: 7.853

Review 3.  Nicotinic modulation of neuronal networks: from receptors to cognition.

Authors:  Huibert D Mansvelder; Karlijn I van Aerde; Jonathan J Couey; Arjen B Brussaard
Journal:  Psychopharmacology (Berl)       Date:  2005-07-02       Impact factor: 4.530

4.  Latent class subtyping of attention-deficit/hyperactivity disorder and comorbid conditions.

Authors:  Maria T Acosta; F Xavier Castellanos; Kelly L Bolton; Joan Z Balog; Patricia Eagen; Linda Nee; Janet Jones; Luis Palacio; Christopher Sarampote; Heather F Russell; Kate Berg; Mauricio Arcos-Burgos; Maximilian Muenke
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2008-07       Impact factor: 8.829

Review 5.  Functional brain imaging of nicotinic effects on higher cognitive processes.

Authors:  Paul A Newhouse; Alexandra S Potter; Julie A Dumas; Christiane M Thiel
Journal:  Biochem Pharmacol       Date:  2011-06-13       Impact factor: 5.858

6.  Decreased α4β2 nicotinic receptor number in the absence of mRNA changes suggests post-transcriptional regulation in the spontaneously hypertensive rat model of ADHD.

Authors:  Mattis B Wigestrand; Yann S Mineur; Christopher J Heath; Frode Fonnum; Marina R Picciotto; Sven Ivar Walaas
Journal:  J Neurochem       Date:  2011-09-01       Impact factor: 5.372

Review 7.  ADHD and smoking: from genes to brain to behavior.

Authors:  Francis Joseph McClernon; Scott Haden Kollins
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

8.  ADHD latent class clusters: DSM-IV subtypes and comorbidity.

Authors:  Josephine Elia; Mauricio Arcos-Burgos; Kelly L Bolton; Paul J Ambrosini; Wade Berrettini; Maximilian Muenke
Journal:  Psychiatry Res       Date:  2009-11-08       Impact factor: 3.222

9.  Attention-Deficit Hyperactivity Disorder in the post-genomic era.

Authors:  Philip Asherson
Journal:  Eur Child Adolesc Psychiatry       Date:  2004       Impact factor: 4.785

10.  Converging pharmacological and genetic evidence indicates a role for steroid sulfatase in attention.

Authors:  William Davies; Trevor Humby; Wendy Kong; Tamara Otter; Paul S Burgoyne; Lawrence S Wilkinson
Journal:  Biol Psychiatry       Date:  2009-02-28       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.